A self-powered bidirectional partition microfluidic chip with embedded microwells for highly sensitive detection of EGFR mutations in plasma of non-small cell lung cancer patients

被引:18
|
作者
Wu, Wenshuai [1 ,2 ]
Wu, Fengtian [3 ]
Zhang, Shan [1 ,2 ]
Ding, Xiong [1 ,2 ]
Zhang, Tao [1 ]
Yang, Ying [3 ]
Mu, Ying [1 ]
机构
[1] Zhejiang Univ, Res Ctr Analyt Instrumentat, Inst Cyber Syst & Control, State Key Lab Ind Control Technol, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med,Collaborat Innovat Ctr Diag & Treatment, Natl Clin Res Ctr Infect Dis,State Key Lab Diag &, Hangzhou 310058, Peoples R China
基金
国家重点研发计划;
关键词
Digital PCR chip; Bidirectional partition network; Embedded microwell; Self-powered; CtDNA analysis; Tumor dynamics monitoring; GROWTH-FACTOR RECEPTOR; CIRCULATING TUMOR DNA; DROPLET DIGITAL PCR; KRAS MUTATIONS; ABSOLUTE QUANTIFICATION; PDMS; PLATFORM;
D O I
10.1016/j.talanta.2020.121426
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Circulating tumor DNA (ctDNA) is a promising biomarker for tumor genotyping and therapy monitoring. Herein, we developed a digital PCR chip with embedded microwell and bidirectional partition network for highly sensitive ctDNA analysis. The embedded microwell contributes to increasing microreaction density (up to 7000 microwells/cm(2)) and reducing evaporation during amplification. The bidirectional partition network can achieve fast and random distribution of targets, ensuring the precise quantification of nucleic acid. We used plasmids, artificial samples and 32 clinical blood samples from non-small cell lung cancer patients to test the performance of this platform. The results demonstrated that our chip has not only comparable quantification performance to commercial counterpart but also the ability to detect EGFR mutations with as low as 0.01% mutation rate and 20 alter molecules in 27 ng genomic DNA. The identification of EGFR mutations in plasma using developed chip exhibited 85.71% sensitivity and 94.44% specificity for L858R mutation and 100% sensitivity and 86.96% specificity for T790 M mutation. Moreover, the monitoring of mutant allele in plasma was accomplished in this work. In conclusion, the developed chip has a potential in lung tumor genotyping and therapy monitoring for precision medicine, even other tumors.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer
    Ryu, Woo Kyung
    Yong, Seung Hyun
    Lee, Sang Hoon
    Gwon, Hye Ran
    Kim, Hye Ryun
    Hong, Min Hee
    Oh, Go Eun
    Jung, Sehee
    Kim, Chi Young
    Chang, Yoon Soo
    Kim, Eun Young
    LUNG CANCER, 2023, 186
  • [32] Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer
    Akca, Hakan
    Demiray, Aydin
    Yaren, Arzu
    Bir, Ferda
    Koseler, Aylin
    Iwakawa, Reika
    Bagci, Gulseren
    Yokota, Jun
    CANCER GENETICS, 2013, 206 (03) : 73 - 80
  • [33] Serial monitoring of EGFR mutations in plasma and matched tissue from EGFR mutant non-small cell lung cancer patients on erlotinib
    Paweletz, Cloud P.
    Oxnard, Geoffrey R.
    Kuang, Yanan
    O'Connell, Allison
    Yanagita, Masahiko
    Messineo, Melissa M.
    Kirschmeier, Paul
    English, Jessie M.
    Jackman, David M.
    Jaenne, Pasi A.
    CANCER RESEARCH, 2014, 74 (19)
  • [34] DETECTION OF EGFR MUTATIONS IN THE CEREBROSPINAL FLUID OF NON-SMALL CELL LUNG CANCERS
    Le Rhun, Emilie
    Gregoire, Valerie
    Girard, Edwina
    Baranzelli, Anne
    Baldacci, Simon
    Descarpentries, Clotilde
    Maurage, Claude Alain
    Cortot, Alexis B.
    Escande, Fabienne
    NEURO-ONCOLOGY, 2016, 18 : 33 - 33
  • [35] Highly sensitive and simultaneous detection of ctDNAs related to non-small cell lung cancer in serum using a catalytic hairpin assembly strategy in a SERS microfluidic chip
    Cao, Xiaowei
    Mao, Yu
    Gu, Yuexing
    Ge, Shengjie
    Lu, Wenbo
    Gu, Yingyan
    Li, Zhiyue
    JOURNAL OF MATERIALS CHEMISTRY B, 2022, 10 (32) : 6194 - 6206
  • [36] Determination of plasma EGFR mutations from non-small cell lung cancer patients at Bach Mai Hospital.
    Cam Phuong Pham
    Khoa Trong Mai
    Nguyen Thuan Loi
    Ngo Thi Thu Hien
    Quynh Thi Thuy Vo
    Ha Dinh Tran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Disparities of EGFR Mutations Between Biopsy and Rebiopsy in Non-Small Cell Lung Cancer Patients
    Yan, S.
    Li, H.
    Liu, X.
    Liu, Y.
    Ma, L.
    Liu, Y.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1088 - S1088
  • [38] EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study
    Bircan, Sema
    Baloglu, Huseyin
    Kucukodaci, Zafer
    Bircan, Ahmet
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [39] EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study
    Sema Bircan
    Huseyin Baloglu
    Zafer Kucukodaci
    Ahmet Bircan
    Medical Oncology, 2014, 31
  • [40] Assessment of EGFR mutations in patients diagnosed of squamous non-small cell lung cancer (NSCLC).
    Lobo, Francisco
    Domine, Manuel
    Rojo, Federico
    Izarzugaza, Yann
    Leon, Ana
    Casado, Victoria
    Jesus Fernandez-Acenero, Maria
    Rubio, Gustavo
    Ignacio Martin-Valades, Jose
    Luis Arranz, Juan
    Serrano, Gloria
    Carames, Cristina
    Cordova, Sharon
    Madoz, Juan
    Zazo, Sandra
    Rincon, Raul
    Canadas, Carmen
    Perez-Gonzalez, Nuria
    Campos, Angel
    Garcia-Foncillas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)